Palatin Technologies, Inc. Common Stock (PTN) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.417x

Based on the latest financial reports, Palatin Technologies, Inc. Common Stock (PTN) has a cash flow conversion efficiency ratio of -0.417x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.42 Million) by net assets ($10.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Palatin Technologies, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Palatin Technologies, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (1996–2025)

This chart illustrates how Palatin Technologies, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Palatin Technologies, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Palatin Technologies, Inc. Common Stock ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Retractable Technologies Inc
NYSE MKT:RVP
-0.008x
Destinasi Tirta Nusantara Tbk
JK:PDES
0.250x
Performance Shipping Inc
NASDAQ:PSHG
0.043x
Vaswani Industries Limited
NSE:VASWANI
0.072x
DUG Foodtech AB (publ)
ST:VUXEN
0.090x
Kumho Electric
KO:001210
0.274x
Greenidge Generation Holdings Inc
NASDAQ:GREE
-0.002x
Bharat Gears Limited
NSE:BHARATGEAR
0.130x

Annual Cash Flow Conversion Efficiency for Palatin Technologies, Inc. Common Stock (1996–2025)

The table below shows the annual cash flow conversion efficiency of Palatin Technologies, Inc. Common Stock from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Palatin Technologies, Inc. Common Stock.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 $-4.78 Million $-21.31 Million 4.460x -98.42%
2024-06-30 $-111.50K $-31.46 Million 282.173x +1865.82%
2023-06-30 $-1.98 Million $-28.42 Million 14.354x +880.37%
2022-06-30 $16.27 Million $-29.92 Million -1.839x -303.25%
2021-06-30 $49.65 Million $-22.65 Million -0.456x -188.49%
2020-06-30 $80.17 Million $41.33 Million 0.515x +337.94%
2019-06-30 $100.55 Million $-21.78 Million -0.217x -443.00%
2018-06-30 $26.96 Million $1.70 Million 0.063x +102.53%
2017-06-30 $-5.16 Million $12.88 Million -2.494x -192.61%
2016-06-30 $-17.59 Million $-47.36 Million 2.693x +346.07%
2015-06-30 $12.20 Million $-13.36 Million -1.095x +12.23%
2014-06-30 $9.79 Million $-12.21 Million -1.247x -109.95%
2013-06-30 $22.98 Million $-13.65 Million -0.594x +92.98%
2012-06-30 $1.83 Million $-15.49 Million -8.459x -1295.05%
2011-06-30 $18.19 Million $-11.03 Million -0.606x +1.39%
2010-06-30 $9.32 Million $-5.73 Million -0.615x +62.57%
2009-06-30 $3.31 Million $-5.44 Million -1.643x +47.69%
2008-06-30 $6.55 Million $-20.58 Million -3.141x -163.94%
2007-06-30 $18.53 Million $-22.05 Million -1.190x +7.13%
2006-06-30 $18.30 Million $-23.45 Million -1.281x -133.44%
2005-06-30 $9.23 Million $-5.06 Million -0.549x +55.18%
2004-06-30 $19.39 Million $-23.74 Million -1.225x -14.86%
2003-06-30 $18.66 Million $-19.89 Million -1.066x +29.55%
2002-06-30 $8.69 Million $-13.15 Million -1.513x -114.75%
2001-06-30 $11.92 Million $-8.40 Million -0.705x +43.02%
2000-06-30 $6.91 Million $-8.54 Million -1.237x +96.43%
1999-06-30 $300.00K $-10.40 Million -34.667x -1492.79%
1998-06-30 $3.40 Million $-7.40 Million -2.176x -420.23%
1997-06-30 $9.80 Million $-4.10 Million -0.418x +56.18%
1996-06-30 $2.84 Million $-2.71 Million -0.955x --

About Palatin Technologies, Inc. Common Stock

NASDAQ:PTN USA Biotechnology
Market Cap
$20.85 Million
Market Cap Rank
#24997 Global
#5257 in USA
Share Price
$11.72
Change (1 day)
-4.33%
52-Week Range
$11.72 - $14.61
All Time High
$14.61
About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more